AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

1-32. (cancelled)

33. (previously presented) An isolated protein that comprises or is constituted by the amino acid sequence of SEQ ID NO: 1.

34. (previously presented) The isolated protein of claim 33, wherein said protein comprises or is constituted by the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 3.

35. (previously presented) An isolated nucleotide sequence encoding the protein that comprises or is constituted by the amino acid sequence of SEQ ID NO: 1.

36. (currently amended) A recombinant vector comprising a nucleotide sequence encoding ~~the~~ an isolated protein ~~as defined in claim 33~~ wherein the isolated protein comprises or is constituted by the amino acid sequence of SEQ ID NO: 1.

37. (previously presented) The recombinant vector according to claim 36, wherein said recombinant vector is a plasmid, a cosmid, a phage, or a virus DNA.

38. (currently amended) The recombinant vector according to claim 36, further comprising operable elements for expression in a host cell of the isolated protein encoded by the nucleotide sequence, inserted into ~~a~~ said vector.

39. (currently amended) A host cell transformed with a recombinant vector containing a nucleotide sequence encoding ~~the~~ an isolated protein ~~as defined in claim 36~~ wherein the isolated protein comprises or is constituted by the amino acid sequence of SEQ ID NO: 1.

40. (previously presented) The host cell according to claim 39, said host cell being chosen from bacteria, yeast, fungi, plant cells, or mammalian cells.

41. (previously presented) A pharmaceutical composition comprising, as active ingredient, the isolated protein according to claim 33, in combination with a pharmaceutically acceptable vehicle.

42. (previously presented) A pharmaceutical composition, comprising as active ingredient, a protein represented by the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 3, in combination with a pharmaceutically acceptable vehicle.

43. (currently amended) The pharmaceutical composition according to claim 41, in which the isolated protein[[,]] is in combination with a ~~variant of the~~ paraoxonase protein comprising ~~the~~ an amino acid sequence selected from the group consisting of: SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6.

44. (currently amended) The pharmaceutical composition according to claim 43, wherein the isolated protein is the isolated protein of SEQ ID NO: 2 or SEQ ID NO: 3.

45. (currently amended) A combination product comprising:

at least the isolated protein according to claim 33, and

at least one ~~variant of the~~ paraoxonase protein consisting of the amino acid sequence selected from the group consisting of: SEQ ID NO: 4, ~~of~~ SEQ ID NO: 5, and SEQ ID NO: 6,

for simultaneous or separate use, or use spread over time, intended for the prophylaxis or treatment of intoxications caused by insecticides or nerve agents.

46. (currently amended) The combination product according to claim 45, wherein said isolated protein is the isolated protein of SEQ ID NO: 2 or SEQ ID NO: 3.

47. (previously presented) The combination product according to claim 45, wherein said nerve agents are soman, VX, sarin, or tabun.

48 – 54. (cancelled)

55. (new) A method for determining the concentration in human plasma of the isolated protein according to claim 33, said method being chosen from:

- eletrophoretic methods;
- purification of the protein;
- quantification of protein activity; and
- immunoassay of the protein using polyclonal/monoclonal antibodies directed against said protein.

56. (new) The method for determining the concentration in human plasma of the isolated protein according to claim 55, wherein the immunoassay is an ELISA-type immunoassay.

57. (new) The method according to claim 55, wherein said isolated protein is the isolated protein of SEQ ID NO: 2 or SEQ ID NO: 3.